You are correct...the data must continue to be good. I would expect the two upcoming presentations to review the current data to prepare the way for the Q4 release of new data. I hope they will tell us about the reason for the delay of the HS-110 and cyclophosphamide trial data. The most obvious explanation is that there is very good overall survival data. I look forward to learning more.
2016 Aegis Growth Conference
Date: Wednesday, September 21, 2016 Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) Location: Encore at Wynn Las Vegas Webcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
OktoberINVESTfest 5th Annual Investors Conference
Date: Wednesday, September 28, 2016 Time: 1:15 p.m. Eastern Time Location: The New York Academy of Sciences
News 
Market Data 
Discover 
